TrialBMC cancer2020

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.

Thomas Decker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.